US 8,088,584 B2 · LTBP2 as a biomarker and diagnostic target

Abstract

The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

Claims4

Dependent claims

A method of using latent TGFβ binding protein 2 (LTBP2) as a biomarker for heart failure, comprising:

(i) measuring the level of LTBP2 mRNA in a heart tissue sample obtained from a mammal,
(ii) comparing the level of LTBP2 mRNA in the heart tissue sample with the level of LTBP2 mRNA in a control sample, and
(iii) diagnosing heart failure based upon the LTBP2 mRNA level of the heart tissue sample in comparison to the control sample,
wherein an increase in the level of LTBP2 mRNA in the heart tissue sample compared to the level of LTBP2 mRNA in the control sample indicates a diagnosis of heart failure.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

12/444,596Filed 2 Oct 2007

Priority

EP 0602159516 Oct 2006

Published

US 2010/0028264 A14 Feb 2010

Granted

3 Jan 2012

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C12Q 2600/136
Oligonucleotides characterized by their use: screening for pharmacological compounds
C12Q 2600/158
Oligonucleotides characterized by their use: expression markers
Y10S 530/841
Proteins from mammals or birds: muscles; heart

LTBP2 as a biomarker and diagnostic target

Life of this patent

LTBP2 as a biomarker and diagnostic target

Life of this patent

Abstract

Claims4